Iron Suspension Injection Supported by Carbon Nanoparticles, Preparation Method, Use, and Method of Use Thereof

Abstract

This application belongs to the field of medicine. Specifically, it proposes a carbon nanoparticle-supported iron suspension injection, a preparation method, and its uses, which contains a carbon nanoparticle suspension injection and ferrous sulfate. The concentration of the carbon nanoparticle suspension injection is 20-100 mg / mL, and the concentration of ferrous ions in the carbon nanoparticle-supported iron suspension injection is 0.5-60 mg / mL. In this application, the carbon nanoparticle-supported iron suspension injection is used in combination with magnetic resonance imaging (MRI) method, which can guide the administration of carbon nanoparticle-supported iron to tumors, uniformly distribute the carbon nanoparticle-supported iron in the tumors after administration, improve the anti-cancer effect of the carbon nanoparticle-supported iron. At the same time, by using MRI, the retention status of the carbon nanoparticle-supported iron at different time points after administration can be observed, the amount and retention time of the drug in the tumor can be known, the retention time of the drug is long, and the mitotic cycles of multiple cancer cells can be effectively covered.

Description

Technical Field

[0001] <Cross - reference to Related Applications> This application claims the priority of a Chinese application with application number 2023103382721 filed on March 31, 2023, and the entire content thereof is incorporated herein by reference.

[0002] This application relates to the medical field. Specifically, it relates to an iron - loaded carbon nanoparticle suspension injection, a preparation method, uses, and a method of using the same.

Background Art

[0003] Iron - loaded carbon nanoparticles are nano - suspensions using carbon nanoparticles as carriers and divalent iron ions or trivalent iron ions as active ingredients. They are anti - cancer innovative drugs. Their mechanism of action is that after locally injecting iron - loaded carbon nanoparticles (CNSI - Fe) into cancer tissue, they enter cancer cells through iron channels overexpressed on the cancer cell membrane. When a large amount of iron ions enter cancer cells rich in hydrogen peroxide (H 2 O 2 ), it undergoes a Fenton reaction with H 2 O 2 to generate a large amount of hydroxyl radicals (·OH). ·OH has extremely strong oxidizing performance and acts on unsaturated poly - fatty acids (UPFAs) in cells to generate a large amount of extremely destructive lipid hydroperoxide (L - OOH), that is, lipid reactive oxygen species (Lipid - ROS). Lipid - ROS destroys cell organelles, leading to cell destruction and causing ferroptosis.

[0004] CNSI - Fe 2+ +H 2 O 2 →ROS(·OH)→L - ROS→Ferroptosis

[0005] In the initial preclinical animal trials, iron-loaded carbon nanoparticles have shown excellent anti-cancer effects and have excellent therapeutic effects against various solid cancers such as colorectal cancer, lung cancer, breast cancer, pancreatic cancer, and undifferentiated thyroid cancer. At the same time, it has the characteristics of good tolerance, high safety, and overcoming multidrug resistance. As a Class 2 anti-cancer drug, iron-loaded carbon nanoparticles have been approved by invention patents in three countries, namely China, the United States, and Japan (the patent name is Nano-carbon-iron composite system and its composition, preparation method, and use), and have four functions: tumor localization, lymphatic tract tracking, primary tumor treatment, and metastatic lymph node treatment, and have synergistic effects with various existing treatment methods such as chemotherapy drugs, radiotherapy, and hyperthermia therapy.

[0006] The administration of iron-loaded carbon nanoparticles to tumors utilizes the carrier effect of carbon nanoparticle suspension injection solution to target Fe 2+ to tumor tissues and achieve the effect of tumor shrinkage through the "ferroptosis" mechanism. By utilizing the preoperative localization function of carbon nanoparticle suspension injection solution, it is beneficial for accurate localization or follow-up observation during surgery. By utilizing the lymphatic tract tracking effect of carbon nanoparticle suspension injection solution, the lymphatic tissue of the tumor can be stained black and accurately excised during subsequent surgery.

[0007] Conventional tumor diagnostic techniques such as B-ultrasound, CT, and MRI can observe the location and size of tumors, but cannot indicate whether the drug has entered the tumor. There are also several new compounds that can be used for tumor diagnosis and treatment. For example, a new type of nanoscale photosensitizer that self-organizes silicon phthalocyanine (PcM) and albumin can achieve tumor-targeted fluorescence imaging and photodynamic immunotherapy, and nanoparticles prepared by combining iron oxide nanocrystals with folic acid and doxorubicin can be used for nuclear magnetic resonance imaging and cancer treatment.

[0008] The conventional carbon nanoparticle-supported iron suspension injection is used for anti-tumor treatment and has relatively good effects. However, its administration method is intratumoral injection. To achieve the optimal effect, the drug needs to be evenly distributed during the injection. After administering carbon nanoparticle-supported iron into the tumor, only the distribution of the drug on the tumor surface can be observed, and the distribution of the drug within the tumor cannot be observed. As a result, it may lead to uneven distribution of the drug and affect the effect of the drug. Moreover, since the tumor is located in the human body, the amount and retention status of the drug at the tumor site cannot be known.

Summary of the Invention

Problems to be Solved by the Invention

[0009] The object of the present application is to provide the use of a carbon nanoparticle-supported iron suspension injection, which can solve the problems in the prior art that after administering carbon nanoparticle-supported iron into the tumor, only the distribution of the drug on the tumor surface can be observed, the distribution of the drug within the tumor cannot be observed, which may lead to uneven distribution of the drug and affect the effect of the drug, and since the tumor is located in the human body, the amount and retention status of the drug at the tumor site cannot be known.

Means for Solving the Problems

[0010] To solve the above technical problems, according to some embodiments, the present application provides the use of a carbon nanoparticle-supported iron suspension injection, which is prepared by mixing a carbon nanoparticle suspension injection and ferrous sulfate for injection. The concentration of the carbon nanoparticle suspension injection is 20 - 100 mg / mL, and the concentration of ferrous iron ions in the carbon nanoparticle-supported iron suspension injection is 0.5 - 60 mg / mL. The carbon nanoparticle-supported iron suspension injection is used as a contrast agent after being injected into the tumor to display its distribution status in the tumor by nuclear magnetic resonance imaging.

[0011] Furthermore, the concentration of the carbon nanoparticle suspension injection is 50 mg / mL, and the concentration of ferrous iron ions is 15 mg / mL.

[0012] Furthermore, the carbon nanoparticle suspension injection contains an antifoaming agent.

[0013] Furthermore, the particle size of the carbon nanoparticles is 90 - 250 nm, and the pH value is 2.8 - 6.0.

[0014] Furthermore, the antifoaming agent is dimethicone, In the carbon nanoparticle suspension injection per 1000 mL, it contains 20 - 100 g of carbon nanoparticles, 17 - 30 g of poloxamer, 2 - 4 g of sodium citrate, 8 - 10 g of sodium chloride, and 0.05 - 0.5 g of dimethicone, and the balance is water for injection.

[0015] Furthermore, in the carbon nanoparticle suspension injection per 1000 mL, it contains 50 g of carbon nanoparticles, 20 g of poloxamer, 0.2 g of dimethicone, 3 g of sodium citrate, and 9 g of sodium chloride, and the balance is water for injection.

[0016] Furthermore, the carbon nanoparticles are carbon black C40.

[0017] Furthermore, the preparation process of the carbon nanoparticles includes a step of degreasing the carbon nanoparticles with ethyl acetate, a step of washing with nitric acid and then washing with water until the pH value of the carbon nanoparticles stabilizes, and a step of washing with sodium hydroxide and then washing with water until the pH value of the carbon nanoparticles stabilizes.

[0018] Furthermore, the preparation process of each part of the carbon nanoparticle suspension injection includes dissolving 60 mg of sodium citrate, 400 mg of poloxamer, and 4 mg of dimethicone in 20 mL of physiological saline, adding 1000 mg of carbon nanoparticles, homogenizing with a homogenizer for 5 - 10 minutes, and after the homogenization is completed, transferring to a homogenizer and homogenizing multiple times.

[0019] Furthermore, the preparation process of ferrous sulfate in each part includes the steps of dissolving 1490 mg of ferrous sulfate heptahydrate in 20 mL of water for injection, adjusting the pH value to 2.8 with a sulfuric acid solution after complete dissolution, dispensing, freeze-drying, backflushing with nitrogen, and sealing to obtain ferrous sulfate.

Advantages of the Invention

[0020] The above technical solution of the present application has at least the following beneficial technical effects.

[0021] The carbon nanoparticle-supported iron suspension injection is used in combination with magnetic resonance imaging (MRI) to guide the administration of carbon nanoparticle-supported iron to tumors. After administration, the carbon nanoparticle-supported iron can be uniformly distributed in the tumors, improving its anti-cancer effect. At the same time, by using MRI, the retention status of the carbon nanoparticle-supported iron at different time points after administration can be observed, and the amount and retention time of the drug in the tumors can be known. The retention time of the drug is long, and the mitotic cycles of multiple cancer cells can be effectively covered.

Brief Description of the Drawings

[0022] To more clearly explain the technical solutions in the embodiments of the present application or the prior art, the following briefly describes the drawings necessary for use in the embodiments. Obviously, the drawings in the following description are only some embodiments of the present application, and those skilled in the art can obtain other drawings based on these drawings without creative efforts.

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Embodiments for Carrying Out the Invention

[0023] Currently, in the prior art, after administering iron-supported carbon nanoparticles into a tumor, only the distribution of the drug on the tumor surface can be observed, and the distribution of the drug within the tumor cannot be observed. As a result, it leads to a non-uniform distribution of the drug, which may affect the efficacy of the drug. And because the tumor is located within the human body, there is a problem that the amount and retention status of the drug at the tumor site cannot be known.

[0024] To solve the above problems, one embodiment of the present application provides the use of an iron-supported carbon nanoparticle suspension injection, which is prepared by mixing a carbon nanoparticle suspension injection and ferrous sulfate. The concentration of the carbon nanoparticle suspension injection is 20 - 100 mg / mL, and the concentration of ferrous ions in the iron-supported carbon nanoparticle suspension injection is 0.5 - 60 mg / mL. Optionally, when measured based on the concentration of ferrous sulfate in the iron-supported carbon nanoparticle suspension injection, the concentration range may also be 0.5 - 60 mg / mL.

[0025] Preferably, the concentration of the carbon nanoparticle suspension injection is 50 mg / mL, and the concentration of ferrous ions is 15 mg / mL.

[0026] The iron-supported carbon nanoparticle suspension injection is used as a contrast agent after being injected into the tumor to display its distribution status within the tumor by magnetic resonance imaging.

[0027] In this example, the carbon nanoparticle-supported iron suspension injection (CNSI-Fe) consists of two parts. Component 1 is ferrous sulfate for injection, and component 2 is a carbon nanoparticle suspension injection of a special solvent. During use, ferrous sulfate for injection is dissolved in the carbon nanoparticle suspension injection of the special solvent to form the carbon nanoparticle-supported iron suspension injection. The carbon nanoparticle-supported iron is a nano-suspension type anti-cancer drug with carbon nanoparticles as the carrier and divalent iron ions or trivalent iron ions as the active ingredient. Since the carbon nanoparticle-supported iron contains iron ions, it can be developed by a nuclear magnetic resonance imaging system. The carbon nanoparticle-supported iron suspension injection is used in combination with the nuclear magnetic resonance imaging method, which can guide the administration of the carbon nanoparticle-supported iron and uniformly distribute it in the tumor, thereby achieving the effect of improving the anti-cancer effect of the carbon nanoparticle-supported iron. At the same time, the amount and residence time of the drug in the tumor can be observed.

[0028] The specific operation is as follows. Before the first administration of the carbon nanoparticle-supported iron suspension injection, in order to facilitate the administration of the carbon nanoparticle-supported iron, the position and size of the tumor are determined by MRI (nuclear magnetic resonance imaging method). Before the next administration, the size of the tumor and the distribution of the carbon nanoparticle-supported iron in the tumor are determined by MRI. According to the distribution status of the carbon nanoparticle-supported iron in the tumor, the administration of the carbon nanoparticle-supported iron is guided so that it can be injected into the tumor site where the carbon nanoparticle-supported iron is not distributed, achieving the purpose of uniform distribution of the carbon nanoparticle-supported iron in the tumor, maximizing the anti-cancer effect. Before each subsequent administration, MRI is used to determine the size of the tumor and the distribution of the carbon nanoparticle-supported iron in the tumor to ensure uniform distribution of the carbon nanoparticle-supported iron in the tumor. At the same time, by using MRI, the retention status of the carbon nanoparticle-supported iron in the tumor at different time points after administration can be observed, and the amount and residence time of the drug in the tumor can be known.

[0029] The carbon nanoparticle-supported iron suspension injection is used in combination with magnetic resonance imaging to guide the administration of carbon nanoparticle-supported iron to tumors. After administration, the carbon nanoparticle-supported iron is uniformly distributed within the tumors, improving its anti-cancer effect. At the same time, by using MRI, the retention status of the carbon nanoparticle-supported iron at different time points after administration can be observed, and the amount and retention time of the drug within the tumors can be determined. The drug has a long retention time and can effectively cover the mitotic cycles of multiple cancer cells.

[0030] In one embodiment of the present application, the carbon nanoparticle suspension injection contains an antifoaming agent, eliminating the influence of bubbles generated during the extraction of the drug (carbon nanoparticle suspension injection) and facilitating actual operations.

[0031] Furthermore, the particle size of the carbon nanoparticles is 90 - 250 nm, and the pH value is 2.8 - 6.0.

[0032] Furthermore, the antifoaming agent is dimethicone. In every 1000 mL of the carbon nanoparticle suspension injection, 20 - 100 g of carbon nanoparticles, 17 - 30 g of poloxamer, 0.05 - 0.5 g of dimethicone, 2 - 4 g of sodium citrate, and 8 - 10 g of sodium chloride are included, with the balance being water for injection. Preferably, in every 1000 mL of the carbon nanoparticle suspension injection, 50 g of carbon nanoparticles, 20 g of poloxamer, 0.2 g of dimethicone, 3 g of sodium citrate, and 9 g of sodium chloride are included, with the balance being water for injection.

[0033] Furthermore, the carbon nanoparticles are carbon black C40.

[0034] In one embodiment of the present application, the preparation process of the carbon nanoparticles is a step of degreasing the carbon nanoparticles with ethyl acetate, a step of washing with nitric acid and then washing with water until the pH value of the carbon nanoparticles stabilizes, and a step of washing with sodium hydroxide and then washing with water until the pH value of the carbon nanoparticles stabilizes.

[0035] In one embodiment of the present application, the preparation process of the carbon nanoparticle suspension injection per 20 mL is as follows: Select 400 - 2000 mg of carbon nanoparticles, 340 - 600 mg of poloxamer 340, 1 - 10 mg of dimethicone, 40 - 80 mg of sodium citrate, and 160 - 200 mg of sodium chloride. Use water for injection to make up the remainder. Preferably, dissolve 60 mg of sodium citrate, 400 mg of poloxamer 340, and 4 mg of dimethicone in 20 mL of physiological saline, add 1000 mg of carbon nanoparticles, and homogenize with a homogenizer for 5 - 10 minutes. Set the rotation speed of the homogenizer to 7000 rpm. After homogenization is completed, transfer it to a homogenizing device and homogenize multiple times. Preferably, homogenize 3 times with a homogenization pressure of 20000 psi. This step is included.

[0036] Furthermore, the preparation process of ferrous sulfate in each part is as follows: Dissolve 1490 mg of ferrous sulfate heptahydrate in 20 mL of water for injection. After complete dissolution, adjust the pH value to 2.8 with a sulfuric acid solution, dispense, freeze-dry, backflush with nitrogen, and seal to obtain ferrous sulfate. Preferably, each bottle contains 91 mg of ferrous sulfate. This step is included.

[0037] Finally, extract the carbon nanoparticle suspension injection, add it to ferrous sulfate for injection, and mix uniformly to obtain a carbon nanoparticle-supported iron suspension injection.

[0038] Note that before use, the carbon nanoparticle suspension injection and ferrous sulfate are separately packaged and prepared on-site during use. The specific preparation parameters are as follows.

[0039] When the concentrations of ferrous ions are 3.75 mg / mL, 7.5 mg / mL, 15 mg / mL, 30 mg / mL, and 60 mg / mL respectively, 8 mL, 4 mL, 2 mL, 1 mL, and 0.5 mL of carbon nanoparticle suspension injection are respectively taken with a syringe, and under the condition of air interruption, passed through the rubber stopper of the ferrous sulfate injection bottle, injected into the ferrous sulfate bottle and mixed, shaken well, and after mixing for 5 minutes, shaken well to obtain a carbon nanoparticle-supported iron suspension injection. The ferrous sulfate in each bottle is 91 mg, and the dosage of ferrous iron is 30 mg. The corresponding relationship of specific parameters is as follows.

[0040] When the concentration of ferrous ions is 60 mg / mL, 0.5 mL of carbon nanoparticle suspension injection is taken with a syringe, and under the condition of air interruption, passed through the rubber stopper of the ferrous sulfate injection bottle, injected into the ferrous sulfate bottle and mixed, shaken well, and after mixing for 5 minutes, shaken well to obtain.

[0041] When the concentration of ferrous ions is 30 mg / mL, 1 mL of carbon nanoparticle suspension injection is taken with a syringe, and under the condition of air interruption, passed through the rubber stopper of the ferrous sulfate injection bottle, injected into the ferrous sulfate bottle and mixed, shaken well, and after mixing for 5 minutes, shaken well to obtain.

[0042] When the concentration of ferrous ions is 15 mg / mL, 2 mL of carbon nanoparticle suspension injection is taken with a syringe, and under the condition of air interruption, passed through the rubber stopper of the ferrous sulfate injection bottle, injected into the ferrous sulfate bottle and mixed, shaken well, and after mixing for 5 minutes, shaken well to obtain.

[0043] When the concentration of ferrous ions is 7.5 mg / mL, 4 mL of carbon nanoparticle suspension injection is taken with a syringe, and under the condition of air interruption, passed through the rubber stopper of the ferrous sulfate injection bottle, injected into the ferrous sulfate bottle and mixed, shaken well, and after mixing for 5 minutes, shaken well to obtain.

[0044] When the concentration of ferrous iron is 3.75 mg / mL, take 8 mL of the carbon nanoparticle suspension injection with a syringe, and under the condition of air interruption, pass through the rubber stopper of the ferrous sulfate injection bottle, inject it into the ferrous sulfate bottle and mix, shake well, after mixing for 5 minutes, shake well to obtain it.

[0045] This application conducts the following tests on the carbon nanoparticle-supported iron suspension injection used in combination with the MRI imaging and analysis process.

[0046] (1) In vitro MRI imaging of carbon nanoparticle-supported iron Test materials: Carbon nanoparticle suspension injection, ferrous sulfate for injection Test method: Prepare a series of carbon nanoparticle-supported iron suspension injections with different ferrous iron concentrations, scan them with a 7T nuclear magnetic resonance scanning system for small animals, and observe the imaging colors and T2 values of the carbon nanoparticle-supported iron suspension injections with different iron concentrations. Test results: The carbon nanoparticle-supported iron suspension injection can be imaged in the nuclear magnetic resonance system. The imaging is mainly related to ferrous iron, and the higher the iron concentration, the darker the imaging color and the smaller the T2 value. The specific results are shown in Table 1 and Figure 1.

[0047] Table 1 Concentration and T2 value of ferrous iron in the carbon nanoparticle-supported iron suspension injection JPEG2025518081000002.jpg41170

[0048] Figure 1 shows that the carbon nanoparticle-supported iron suspension injection can be imaged in the nuclear magnetic resonance system, and the higher the iron concentration, the darker the imaging color. In Figure 1, No. 1 represents that the concentration of ferrous iron is 15 mg / mL and the color is black; No. 2 represents that the concentration of ferrous iron is 7.5 mg / mL and the color is dark gray; No. 3 represents that the concentration of ferrous iron is 3.75 mg / mL and the color is gray. As the concentration of ferrous iron decreases, the color becomes lighter.

[0049] (2) In Vivo MRI Imaging of Iron Supported by Carbon Nanoparticles Test Materials: Mouse-derived colorectal cancer CT26.WT cells, RPMI1640 medium for cells, fetal bovine serum (FBS), cell digestive solution pancreatin, penicillin-streptomycin mixture, phosphate buffer solution (PBS, pH value 7.4), carbon nanoparticle-supported iron suspension injection (carbon nanoparticles-ferrous sulfate, carbon nanoparticles: ferrous ion = 50:15 mg / mL). Test Animals: SPF-grade Balb / c mice, female, 4 - 6 weeks old, body weight 20 ± 2 g. During the experiment, they were allowed to eat and drink freely. They were illuminated for 12 h every day and bred in independent air supply isolation cages with 5 mice per cage. Test Method: CT26.WT colorectal cancer cells in the logarithmic growth phase were collected, and the concentration of the cell suspension was adjusted to 3×10 7 cells / mL. The cells were subcutaneously inoculated into the right upper limb of Balb / c mice at 0.1 mL per mouse (containing approximately 3×10 6 cells). When the tumor diameter of the inoculated mice reached 7 - 8 mm, the carbon nanoparticle-supported iron suspension injection was injected into the tumor. On the 0th, 3rd, and 14th days after administration, they were scanned with a 7T nuclear magnetic resonance scanning system for small animals. Test results: The tumors of mice were scanned by a 7T nuclear magnetic resonance scanning system for small animals, and the results of the scanning are shown in Figures 2, 3, 4, and 5. Figure 2 is the MRI image of the mouse before intratumoral injection. Figure 3 is the MRI image on the 0th day after injecting the carbon nanoparticle-loaded iron suspension injection into the tumor of the mouse. After administering the carbon nanoparticle-loaded iron into the tumor, imaging can be performed in the nuclear magnetic resonance system, and the color is black. The carbon nanoparticle-loaded iron is mainly distributed in the center of the tumor, and there is a small area that is not distributed around it. Figure 4 is the MRI image on the 3rd day after injecting the carbon nanoparticle-loaded iron suspension injection into the tumor of the mouse. The tumor shrank slightly 3 days after administration, a large amount of carbon nanoparticle-loaded iron remained, mainly distributed in the center, and there is a small area that is not distributed around it. Figure 5 is the MRI image on the 14th day after injecting the carbon nanoparticle-loaded iron suspension injection into the tumor of the mouse. The tumor shrank slightly 14 days after administration, and relatively more carbon nanoparticle-loaded iron remained, mainly distributed in the center, and there is a small area that is not distributed around it.

[0050] Through the above tests, it was shown that the carbon nanoparticle-loaded iron suspension injection can be used in combination with nuclear magnetic resonance imaging method to guide the administration of carbon nanoparticle-loaded iron into the tumor, and after administration, the carbon nanoparticle-loaded iron can be evenly distributed in the tumor, improving the anti-cancer effect of the carbon nanoparticle-loaded iron. At the same time, by using MRI, the retention status of the carbon nanoparticle-loaded iron at different time points after administration can be observed, the amount and retention time of the drug in the tumor can be known, the retention time of the drug is long, and the mitotic cycles of multiple cancer cells can be effectively covered.

[0051] It should be understood that the above specific embodiments of the present application are only for exemplarily explaining or interpreting the principle of the present application, and do not constitute a limitation of the present application. Therefore, any modifications, equivalent substitutions, improvements, etc. made without departing from the spirit and scope of the present application should be included within the protection scope of the present application. Furthermore, the appended claims of the present application are intended to cover all changes and modifications that fall within the scope and boundaries of the appended claims, or equivalents of such scope and boundaries.

Claims

1. A use of a carbon nanoparticle-supported iron suspension for injection, the carbon nanoparticle-supported iron suspension for injection being prepared by mixing a carbon nanoparticle-supported iron suspension for injection and ferrous sulfate, the carbon nanoparticle-supported iron suspension for injection having a concentration of 20 to 100 mg / mL, and a ferrous ion concentration in the carbon nanoparticle-supported iron suspension for injection being 0.5 to 60 mg / mL; The carbon nanoparticle-loaded iron suspension for injection is used as a developer after being injected into a tumor in order to display its distribution and retention in the tumor by nuclear magnetic resonance imaging.

2. The use of the carbon nanoparticle-loaded iron suspension injection according to claim 1, characterized in that the concentration of the carbon nanoparticle suspension injection is 50 mg / mL, and the concentration of the ferrous ions is 15 mg / mL.

3. The use of the carbon nanoparticle-loaded iron suspension injection according to claim 1, characterized in that the carbon nanoparticle suspension injection contains an antifoaming agent.

4. The use of carbon nanoparticle-loaded iron suspension for injection according to claim 1, characterized in that the particle size of carbon nanoparticle-loaded iron suspension for injection is 90-250nm, and the pH value is 2.8-6.

0.

5. The defoaming agent is dimethicone. The use of the carbon nanoparticle-supported iron suspension injection according to claim 2, characterized in that the carbon nanoparticle suspension injection contains 20 to 100 g of carbon nanoparticles, 17 to 30 g of poloxamer, 2 to 4 g of sodium citrate, 8 to 10 g of sodium chloride, and 0.05 to 0.5 g of dimethicone per 1000 mL, with the remainder being water for injection.

6. The carbon nanoparticle-supported iron suspension injection according to claim 5, characterized in that per 1000 mL of the carbon nanoparticle suspension injection, it contains 50 g of carbon nanoparticles, 20 g of poloxamer, 0.2 g of dimethicone, 3 g of sodium citrate, and 9 g of sodium chloride, with the remainder being water for injection.

7. The carbon nanoparticle-loaded iron suspension injection according to claim 5, characterized in that the carbon nanoparticles are carbon black C40.

8. The process for preparing the carbon nanoparticles includes: The carbon nanoparticle-loaded iron suspension injection solution according to claim 5, further comprising the steps of: degreasing the carbon nanoparticles with ethyl acetate; washing with nitric acid, followed by washing with water until the pH value of the carbon nanoparticles is stable; and washing with sodium hydroxide, followed by washing with water until the pH value of the carbon nanoparticles is stable.

9. The preparation process of the carbon nanoparticle suspension injection solution for each part is as follows: The carbon nanoparticle-loaded iron suspension injection according to claim 5, characterized in that it comprises the steps of dissolving 60 mg of sodium citrate, 400 mg of poloxamer, and 4 mg of dimethicone in 20 mL of physiological saline, adding 1000 mg of carbon nanoparticles, and homogenizing with a homogenizer for 5 to 10 minutes, and transferring the homogenization to a homogenizer after homogenization is completed and homogenizing multiple times.

10. The carbon nanoparticle-loaded iron suspension injection according to claim 5, characterized in that the preparation process of each portion of ferrous sulfate includes the steps of dissolving 1490 mg of ferrous sulfate heptahydrate in 20 mL of water for injection, adjusting the pH value to 2.8 with sulfuric acid solution after dissolution is complete, dispensing, lyophilizing, backflushing with nitrogen, and sealing to obtain ferrous sulfate.

Images